276 related articles for article (PubMed ID: 7149814)
21. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
[TBL] [Abstract][Full Text] [Related]
23. Immunocytochemical localization of estrogen receptor in human breast tissue.
Walker KJ; Bouzubar N; Robertson J; Ellis IO; Elston CW; Blamey RW; Wilson DW; Griffiths K; Nicholson RI
Cancer Res; 1988 Nov; 48(22):6517-22. PubMed ID: 3052804
[TBL] [Abstract][Full Text] [Related]
24. Survival with breast cancer: the importance of estrogen receptor quantity.
Shek LL; Godolphin W
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):243-50. PubMed ID: 2702979
[TBL] [Abstract][Full Text] [Related]
25. In vitro clonogenic growth and metastatic potential of human operable breast cancer.
Nomura Y; Tashiro H; Hisamatsu K
Cancer Res; 1989 Oct; 49(19):5288-93. PubMed ID: 2766296
[TBL] [Abstract][Full Text] [Related]
26. Disease-free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow-up.
Raemaekers JM; Beex LV; Koenders AJ; Pieters GF; Smals AG; Benraad TJ; Kloppenborg PW
Breast Cancer Res Treat; 1985; 6(2):123-30. PubMed ID: 4052639
[TBL] [Abstract][Full Text] [Related]
27. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
28. Progesterone and estrogen receptors as prognostic variables in breast cancer.
Mason BH; Holdaway IM; Mullins PR; Yee LH; Kay RG
Cancer Res; 1983 Jun; 43(6):2985-90. PubMed ID: 6850609
[TBL] [Abstract][Full Text] [Related]
29. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
30. Estrogen receptor determination and long term survival of patients with carcinoma of the breast.
Crowe JP; Gordon NH; Hubay CA; Shenk RR; Zollinger RM; Brumberg DJ; McGuire WL; Shuck JM
Surg Gynecol Obstet; 1991 Oct; 173(4):273-8. PubMed ID: 1925896
[TBL] [Abstract][Full Text] [Related]
31. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
[TBL] [Abstract][Full Text] [Related]
32. The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery.
Kiba T; Inamoto T; Nishimura T; Ueno M; Yanagihara K; Teramukai S; Kato H; Toi M; Fukushima M
BMC Cancer; 2008 Nov; 8():323. PubMed ID: 18990247
[TBL] [Abstract][Full Text] [Related]
33. Relationship of estrogen and progesterone receptors to prognosis in breast cancer.
Gelbfish GA; Davidson AL; Kopel S; Schreibman B; Gelbfish JS; Degenshein GA; Herz BL; Cunningham JN
Ann Surg; 1988 Jan; 207(1):75-9. PubMed ID: 3337566
[TBL] [Abstract][Full Text] [Related]
34. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B; Jeong JH; Dignam J; Anderson S; Mamounas E; Wickerham DL; Wolmark N
J Natl Cancer Inst Monogr; 2001; (30):62-6. PubMed ID: 11773294
[TBL] [Abstract][Full Text] [Related]
35. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
36. [Steroid hormone receptors and survival in breast cancer patients].
Ivanova OA; Tsyrlina EV; Moiseenko VM; Semiglazov VF
Vopr Onkol; 1986; 32(6):71-6. PubMed ID: 3727485
[TBL] [Abstract][Full Text] [Related]
37. Oestrogen receptors, nodes and stage as predictors of post-recurrence survival in 457 breast cancer patients.
Shek LL; Godolphin W; Spinelli JJ
Br J Cancer; 1987 Dec; 56(6):825-9. PubMed ID: 3435707
[TBL] [Abstract][Full Text] [Related]
38. Volume-based parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography improve disease recurrence prediction in postmastectomy breast cancer patients with 1 to 3 positive axillary lymph nodes.
Nakajima N; Kataoka M; Sugawara Y; Ochi T; Kiyoto S; Ohsumi S; Mochizuki T
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):738-46. PubMed ID: 24064322
[TBL] [Abstract][Full Text] [Related]
39. [PS2 as a prognostic factor in 1065 cases of human breast cancer. A multicenter study].
Besse G; Kwiatkowski F; Gaillard G; Daver A; Dalifard I; Basuyau JP; Brunelle P; Wafflart J; Angibeau RM; Auvray E
Bull Cancer; 1994 Apr; 81(4):289-96. PubMed ID: 7703545
[TBL] [Abstract][Full Text] [Related]
40. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
